Investigational drug · Phase 3
AR882
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gout, Hyperuricemia, Gout Chronic.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
11
Any phase or sponsor naming "AR882"
First trial start
2024
Jun 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AR882", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gout
- Hyperuricemia
- Gout Chronic
- Arthritis, Gouty
- Gouty Arthritis
- Refractory Gout
- Uncontrolled Gout
- Tophaceous Gout
Approved drugs for the same conditions: Gout
Largest trials
Live from ClinicalTrials.gov: studies naming "AR882" as an intervention, largest first.
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)Pivotal-lookingCompleted
Arthrosi TherapeuticsIndustry
NCT06846515 · 866 participants · Start Mar 11, 2025 · Primary completion Aug 31, 2026
Drug: AR882 50 mg; AR882 75 mg and 1 more · For: Gout; Arthritis, Gouty; Hyperuricemia and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Peoria, Arizona · 83 sites in all
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)Pivotal-lookingCompleted
Arthrosi TherapeuticsIndustry
NCT06439602 · 818 participants · Start Jun 26, 2024 · Primary completion Mar 20, 2026
Drug: AR882 50 mg; AR882 75 mg and 1 more · For: Gout; Arthritis, Gouty; Hyperuricemia and 1 more
Sites: Foley, Alabama; Anchorage, Alaska; Peoria, Arizona · 68 sites in all
- Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and HyperuricemiaPivotal-lookingStatus unknown
Guangzhou Ruianbo Pharmaceutical Technology Co., LtdIndustry
NCT06603142 · 636 participants (planned) · Start Apr 22, 2024 · Primary completion Apr 2026
Drug: Febuxostat 20MG Tablets; Febuxostat 20MG Placebo and 6 more · For: Primary Gout; Hyperuricemia
Sites: Beijing, China
- Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout PatientsPivotal-lookingCompleted
Arthrosi TherapeuticsIndustry
NCT05119686 · 140 participants · Start Nov 16, 2021 · Primary completion Nov 17, 2022
Drug: AR882 Dose 1; AR882 Dose 2 and 1 more · For: Gout; Arthritis, Gouty; Hyperuricemia and 1 more
Sites: Gilbert, Arizona; Sun City, Arizona; Tucson, Arizona · 23 sites in all
Arthrosi TherapeuticsIndustry
NCT04347005 · 64 participants · Start Jan 22, 2019 · Primary completion Jul 31, 2019
Drug: Cohort 1: AR882; Cohort 2: AR882 and 7 more · For: Healthy Volunteers
Sites: Melbourne, Australia
Arthrosi TherapeuticsIndustry
NCT04646889 · 46 participants · Start Jan 14, 2021 · Primary completion Jun 27, 2022
Drug: AR882 Single Dose; AR882 Multiple Dose · For: Renal Impairment
Sites: Orlando, Florida; Dallas, Texas; Auckland, New Zealand · 4 sites in all
Arthrosi TherapeuticsIndustry
NCT05253833 · 42 participants · Start Aug 12, 2022 · Primary completion Aug 13, 2024
Drug: AR882 Dose 1; AR882 Dose 2 and 1 more · For: Gout; Arthritis, Gouty; Hyperuricemia and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City, Arizona · 12 sites in all
Arthrosi TherapeuticsIndustry
NCT04314986 · 30 participants · Start Jun 28, 2019 · Primary completion Sep 18, 2019
Drug: Cohort 1: AR882 or placebo; Cohort 2: AR882 or placebo and 2 more · For: Healthy Volunteers
Sites: Melbourne, Australia
- Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout PatientsCompleted
Arthrosi TherapeuticsIndustry
NCT04155918 · 30 participants · Start Feb 3, 2020 · Primary completion Sep 3, 2020
Drug: Group 1: AR882 Alone and in Combination with Febuxostat (FBX); Group 2: AR882 Alone and in Combination with Allopurinol (ALLO) · For: Gout Patients
Sites: Christchurch, New Zealand
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsActive, not recruiting
Arthrosi TherapeuticsIndustry
NCT07116746 · 15 participants (planned) · Start Dec 3, 2025 · Primary completion Nov 2026
Drug: AR882 75 mg; XOI Low Dose and 1 more · For: Gout; Gouty Arthritis; Hyperuricemia and 4 more
Sites: Margate, Florida; Miami, Florida; Tampa, Florida · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [Comprehensive management of tophaceous wound].
He G, Lu S, Lu X, et al. · Zhejiang Da Xue Xue Bao Yi Xue Ban 2025
Also in development for Gout
- DotinuradPhase 33 trials
Crystalys Therapeutics · Gout, Tophaceous Gout
- TigulixostatIBI128, LC350189Phase 33 trials
Innovent Biologics Technology Limited (Shanghai R&D Center) · Gout, Hyperuricemia, Gout Flare
- ABP-671Phase 32 trials
Atom Therapeutics Co., Ltd · Chronic Kidney Disease, Gout
- PRX-115Phase 21 trial
Protalix · Gout
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.